Veregen sinecatechins regulatory update

Medigene submitted MAAs in 8 European countries for Veregen sinecatechins to treat external genital and perianal warts under the Mutual Recognition Procedure. The company expects a decision next half from the U.K., Ireland, Italy, Portugal, Croatia, Latvia, Lithuania and Estonia. The topical formulation of polyphenols extracted from green tea leaves is marketed in the U.S., Canada, Taiwan, Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary and Poland. ...